Gene: SLC25A44

9673
-
solute carrier family 25 member 44
protein-coding
1q22
Ensembl:ENSG00000160785 MIM:610824 Vega:OTTHUMG00000014816 UniprotKB:Q96H78
NC_000001.11
PubMed|SNP Mapped
1   ANCO-SNPs
ND|AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.127e-2 (AD)  6.144e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs2241109chr1:156203291 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
AREL10.958
LARP10.955
PPME10.955
EIF4E20.955
POLR3A0.955
CIAPIN10.954
IRGQ0.953
EXTL30.951
ATP1A10.949
RNF410.949

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.529
OR4F29-0.486
MYL3-0.452
HEY2-0.446
CSAG1-0.426
ASB4-0.424
YES1-0.421
MTRNR2L9-0.418
MBNL3-0.416
COPZ2-0.415

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
D000082AcetaminophenAcetaminophen results in increased expression of SLC25A44 mRNA25704631
D000082AcetaminophenAcetaminophen affects the expression of SLC25A44 mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of SLC25A44 mRNA27153756
D001280AtrazineAtrazine results in decreased expression of SLC25A44 mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SLC25A44 mRNA19770486
C006780bisphenol Abisphenol A results in increased expression of SLC25A44 mRNA21932408
C006780bisphenol Abisphenol A affects the expression of SLC25A44 mRNA25181051
C074702chromium hexavalent ionchromium hexavalent ion affects the expression of SLC25A44 mRNA28472532
C030973cupric oxidecupric oxide results in increased expression of SLC25A44 mRNA22077320
D016572CyclosporineCyclosporine results in decreased expression of SLC25A44 mRNA20106945|2556210
D004041Dietary FatsDietary Fats results in decreased expression of SLC25A44 mRNA18042831
D004317DoxorubicinDoxorubicin results in decreased expression of SLC25A44 mRNA19277126
D005557FormaldehydeFormaldehyde results in decreased expression of SLC25A44 mRNA20655997
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SLC25A44 mRNA25613284
D008727MethotrexateMethotrexate results in decreased expression of SLC25A44 mRNA24449571
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of SLC25A44 mRNA28001369
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of SLC25A44 mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of SLC25A44 mRNA"25620056
C009618O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate"PON1 gene polymorphism affects the susceptibility to [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of SLC25A44 mRNA]"21673326
C009618O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate"O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in decreased expression of SLC25A44 mRNA"21673326
D000073878Palm OilPalm Oil results in decreased expression of SLC25A44 mRNA18042831
C016030pantogabpantogab results in decreased expression of SLC25A44 mRNA17379144
C568608PCI 5002[PCI 5002 co-treated with Zinc] results in increased expression of SLC25A44 mRNA18593933
D010795Phthalic AcidsPhthalic Acids results in increased expression of SLC25A44 mRNA21061450
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of SLC25A44 mRNA21570461|2637764
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of SLC25A44 mRNA19770486|2629044
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SLC25A44 mRNA25613284
D013849ThimerosalThimerosal results in increased expression of SLC25A44 mRNA27188386
D014050TolueneToluene results in decreased expression of SLC25A44 mRNA22166486
D014415TunicamycinTunicamycin results in increased expression of SLC25A44 mRNA22378314
D014635Valproic AcidValproic Acid affects the expression of SLC25A44 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of SLC25A44 mRNA23179753|2519280
D014635Valproic AcidValproic Acid affects the expression of SLC25A44 mRNA17292431
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of SLC25A44 gene25560391
C025643vinclozolinvinclozolin results in decreased expression of SLC25A44 mRNA23034163
D015032Zinc[PCI 5002 co-treated with Zinc] results in increased expression of SLC25A44 mRNA18593933

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
GO:0055085transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26670299Genetic risk factors for spontaneous intracerebral haemorrhage. (2016 Jan)Carpenter AMNat Rev Neurol